[S02DA03, antipyrine, The metabolism of Hydroxychloroquine can be decreased when combined with Antipyrine.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hydroxychloroquine.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Hydroxychloroquine.]
[L04AA27, fingolimod, Hydroxychloroquine may increase the immunosuppressive activities of Fingolimod.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Hydroxychloroquine.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Hydroxychloroquine.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be increased when used in combination with Hydroxychloroquine.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Sulpiride.]
[N03AX03, sulthiame, The therapeutic efficacy of Sulthiame can be decreased when used in combination with Hydroxychloroquine.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be increased when used in combination with Hydroxychloroquine.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be increased when used in combination with Hydroxychloroquine.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Hydroxychloroquine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Hydroxychloroquine.]
[L01CB02, teniposide, The risk or severity of adverse effects can be increased when Teniposide is combined with Hydroxychloroquine.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Hydroxychloroquine.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Lurasidone.]
[A04AD10, dronabinol, The metabolism of Hydroxychloroquine can be decreased when combined with Dronabinol.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Hydroxychloroquine.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Hydroxychloroquine.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Hydroxychloroquine.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Eribulin.]
[R06AD03, thiethylperazine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Thiethylperazine.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Hydroxychloroquine.]
[N05CA19, thiopental, The therapeutic efficacy of Thiopental can be decreased when used in combination with Hydroxychloroquine.]
[N05AB08, thioproperazine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Thiothixene.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Hydroxychloroquine.]
[B01AC05, ticlopidine, The metabolism of Hydroxychloroquine can be decreased when combined with Ticlopidine.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Hydroxychloroquine.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be increased when used in combination with Hydroxychloroquine.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be increased when used in combination with Hydroxychloroquine.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Hydroxychloroquine.]
[N06AF04, tranylcypromine, The metabolism of Hydroxychloroquine can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Hydroxychloroquine.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Hydroxychloroquine.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Triamcinolone is combined with Hydroxychloroquine.]
[N05AB06, trifluoperazine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Trifluoperazine.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Hydroxychloroquine.]
[N05AA05, triflupromazine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Triflupromazine.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Mometasone is combined with Hydroxychloroquine.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Alimemazine.]
[N03AC02, trimethadione, The therapeutic efficacy of Trimethadione can be decreased when used in combination with Hydroxychloroquine.]
[J01EA01, trimethoprim, The metabolism of Hydroxychloroquine can be decreased when combined with Trimethoprim.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Hydroxychloroquine.]
[R06AC04, tripelennamine, The metabolism of Hydroxychloroquine can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Hydroxychloroquine.]
[J01FA08, troleandomycin, The metabolism of Hydroxychloroquine can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Hydroxychloroquine can be decreased when combined with Vilazodone.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Hydroxychloroquine.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Belimumab.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Vandetanib.]
[L02BX03, abiraterone, The metabolism of Hydroxychloroquine can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Hydroxychloroquine.]
[J05AP03, boceprevir, The metabolism of Hydroxychloroquine can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Hydroxychloroquine can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Rilpivirine.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Belatacept.]
[N03AX21, ezogabine, The therapeutic efficacy of Ezogabine can be decreased when used in combination with Hydroxychloroquine.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Indacaterol.]
[C08DA01, verapamil, The metabolism of Hydroxychloroquine can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Hydroxychloroquine can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The risk or severity of adverse effects can be increased when Vinblastine is combined with Hydroxychloroquine.]
[L01CA02, vincristine, The risk or severity of adverse effects can be increased when Vincristine is combined with Hydroxychloroquine.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Hydroxychloroquine.]
[S01AA13, fusidic acid, The metabolism of Hydroxychloroquine can be decreased when combined with Fusidic acid.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Hydroxychloroquine.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Hydroxychloroquine can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The therapeutic efficacy of Levetiracetam can be decreased when used in combination with Hydroxychloroquine.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Hydroxychloroquine.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Brentuximab vedotin.]
[L01ED01, crizotinib, The metabolism of Hydroxychloroquine can be decreased when combined with Crizotinib.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Hydroxychloroquine.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Ziprasidone.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hydroxychloroquine.]
[L01EJ01, ruxolitinib, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Ruxolitinib.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Hydroxychloroquine.]
[C07AB03, atenolol, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Atenolol.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Hydroxychloroquine.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Hydroxychloroquine.]
[J02AC03, voriconazole, The metabolism of Hydroxychloroquine can be decreased when combined with Voriconazole.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Atropine.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Prednylidene.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Hydroxychloroquine.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Hydroxychloroquine.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Hydroxychloroquine.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Hydroxychloroquine.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Hydroxychloroquine.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydroxychloroquine.]
[A08AA11, lorcaserin, The metabolism of Hydroxychloroquine can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Hydroxychloroquine can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Carfilzomib.]
[V03AX03, cobicistat, The metabolism of Hydroxychloroquine can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Hydroxychloroquine can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Hydroxychloroquine can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Bosutinib.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Teriflunomide.]
[A02AA05, magnesium silicate, Magnesium silicate can cause a decrease in the absorption of Hydroxychloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AC02, calcium silicate, Calcium silicate can cause a decrease in the absorption of Hydroxychloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Aldosterone.]
[N05CA04, barbital, The therapeutic efficacy of Barbital can be decreased when used in combination with Hydroxychloroquine.]
[C01AA01, acetyldigitoxin, The serum concentration of Acetyldigitoxin can be increased when it is combined with Hydroxychloroquine.]
[J05AE04, nelfinavir, The metabolism of Hydroxychloroquine can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Bendamustine.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Hydroxychloroquine.]
[N03AX22, perampanel, The therapeutic efficacy of Perampanel can be decreased when used in combination with Hydroxychloroquine.]
[L04AA29, tofacitinib, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Tofacitinib.]
[G04BD10, darifenacin, The metabolism of Hydroxychloroquine can be decreased when combined with Darifenacin.]
[L01EX07, cabozantinib, The metabolism of Hydroxychloroquine can be decreased when combined with Cabozantinib.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Pasireotide.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Hydroxychloroquine.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Hydroxychloroquine.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Hydroxychloroquine.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Bencyclane.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Hydroxychloroquine.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Hydroxychloroquine can be decreased when combined with Glycerol phenylbutyrate.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Pomalidomide.]
[G03XC05, ospemifene, The metabolism of Hydroxychloroquine can be decreased when combined with Ospemifene.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Hydroxychloroquine.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Dimethyl fumarate.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Hydroxychloroquine can be decreased when combined with Tegaserod.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be increased when used in combination with Hydroxychloroquine.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Benzocaine.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be increased when used in combination with Hydroxychloroquine.]
[M01AH01, celecoxib, The metabolism of Hydroxychloroquine can be decreased when combined with Celecoxib.]
[L04AA18, everolimus, The risk or severity of adverse effects can be increased when Everolimus is combined with Hydroxychloroquine.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Hydroxychloroquine.]
[L01EC02, dabrafenib, The serum concentration of Hydroxychloroquine can be decreased when it is combined with Dabrafenib.]
[L01EE01, trametinib, The metabolism of Hydroxychloroquine can be decreased when combined with Trametinib.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be decreased when combined with Hydroxychloroquine.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Bepridil.]
[C02KX05, riociguat, The metabolism of Riociguat can be decreased when combined with Hydroxychloroquine.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be increased when used in combination with Hydroxychloroquine.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Ibrutinib.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Hydroxychloroquine.]
[N03AF04, eslicarbazepine, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Hydroxychloroquine.]
[J05AP05, simeprevir, The metabolism of Hydroxychloroquine can be decreased when combined with Simeprevir.]
[N03AG04, vigabatrin, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Hydroxychloroquine.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Hydroxychloroquine.]
[C07AB04, acebutolol, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Acebutolol.]
[A16AA07, metreleptin, The metabolism of Hydroxychloroquine can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Hydroxychloroquine can be increased when combined with Apremilast.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Hydroxychloroquine.]
[S01ED02, betaxolol, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Betaxolol.]
[C10AB02, bezafibrate, The metabolism of Hydroxychloroquine can be decreased when combined with Bezafibrate.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be increased when used in combination with Hydroxychloroquine.]
[L04AC11, siltuximab, The metabolism of Hydroxychloroquine can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Ceritinib.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Vedolizumab.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Hydroxychloroquine.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Belinostat.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Idelalisib.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Hydroxychloroquine.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Olodaterol.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Peginterferon beta-1a.]
[A16AX10, eliglustat, The metabolism of Hydroxychloroquine can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Hydroxychloroquine can be decreased when combined with Oritavancin.]
[N05AA04, acepromazine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Acepromazine.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be increased when used in combination with Hydroxychloroquine.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Decitabine is combined with Hydroxychloroquine.]
[N04AA02, biperiden, The metabolism of Hydroxychloroquine can be decreased when combined with Biperiden.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Pirfenidone.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Blinatumomab.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Hydroxychloroquine.]
[L01XK01, olaparib, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Olaparib.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Hydroxychloroquine.]
[L04AC10, secukinumab, The metabolism of Hydroxychloroquine can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Palbociclib.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Lenvatinib.]
[L01XH03, panobinostat, The metabolism of Hydroxychloroquine can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Hydroxychloroquine.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Hydroxychloroquine.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Ivabradine.]
[J05AP06, asunaprevir, The metabolism of Hydroxychloroquine can be decreased when combined with Asunaprevir.]
[N05AX16, brexpiprazole, The metabolism of Brexpiprazole can be decreased when combined with Hydroxychloroquine.]
[A04AD14, rolapitant, The metabolism of Hydroxychloroquine can be decreased when combined with Rolapitant.]
[A06AD03, magnesium peroxide, Magnesium peroxide can cause a decrease in the absorption of Hydroxychloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be increased when used in combination with Hydroxychloroquine.]
[S01EC01, acetazolamide, The therapeutic efficacy of Acetazolamide can be decreased when used in combination with Hydroxychloroquine.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be increased when used in combination with Hydroxychloroquine.]
[N05AB07, acetophenazine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Acetophenazine.]
[A02BC03, lansoprazole, The metabolism of Hydroxychloroquine can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Hydroxychloroquine.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Mepolizumab.]
[J02AC05, isavuconazole, The metabolism of Hydroxychloroquine can be decreased when combined with Isavuconazole.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Hydroxychloroquine.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be increased when used in combination with Hydroxychloroquine.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Hydroxychloroquine.]
[A02AB06, aloglutamol, Aloglutamol can cause a decrease in the absorption of Hydroxychloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N03AX23, brivaracetam, The therapeutic efficacy of Brivaracetam can be decreased when used in combination with Hydroxychloroquine.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Ixekizumab.]
[L01XX52, venetoclax, The metabolism of Hydroxychloroquine can be decreased when combined with Venetoclax.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Hydroxychloroquine.]
[A02AD05, aluminum magnesium silicate, Almasilate can cause a decrease in the absorption of Hydroxychloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AB03, aluminum phosphate, Aluminium phosphate can cause a decrease in the absorption of Hydroxychloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Hydroxychloroquine.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Bupivacaine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Hydroxychloroquine can be decreased when combined with Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Buserelin.]
[N05BE01, buspirone, The metabolism of Buspirone can be decreased when combined with Hydroxychloroquine.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Busulfan is combined with Hydroxychloroquine.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Hydroxychloroquine.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Artemether.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Hydroxychloroquine.]
[S01GX07, azelastine, The metabolism of Hydroxychloroquine can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Hydroxychloroquine can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Azithromycin.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Brodalumab.]
[L01EF02, ribociclib, The metabolism of Hydroxychloroquine can be decreased when combined with Ribociclib.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Ocrelizumab.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Hydroxychloroquine.]
[N03AX30, beclamide, The therapeutic efficacy of Beclamide can be decreased when used in combination with Hydroxychloroquine.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be increased when used in combination with Hydroxychloroquine.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Oxybuprocaine.]
[A12AA04, calcium carbonate, Calcium carbonate can cause a decrease in the absorption of Hydroxychloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Hydroxychloroquine.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Hydroxychloroquine.]
[J05AE09, tipranavir, The metabolism of Hydroxychloroquine can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Hydroxychloroquine.]
[L04AB02, infliximab, The metabolism of Hydroxychloroquine can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Hydroxychloroquine can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Hydroxychloroquine.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Sarilumab.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Delafloxacin.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Capecitabine is combined with Hydroxychloroquine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Hydroxychloroquine.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Vorinostat.]
[A02BX12, bismuth subnitrate, Bismuth subnitrate can cause a decrease in the absorption of Hydroxychloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C07AB07, bisoprolol, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Hydroxychloroquine can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Bopindolol.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Hydroxychloroquine.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Hydroxychloroquine.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Budesonide is combined with Hydroxychloroquine.]
[J05AX18, letermovir, The metabolism of Hydroxychloroquine can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Acetyldigoxin.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be increased when used in combination with Hydroxychloroquine.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be increased when used in combination with Hydroxychloroquine.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Acrivastine.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Macimorelin.]
[L02BB05, apalutamide, The metabolism of Hydroxychloroquine can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The therapeutic efficacy of Carbamazepine can be decreased when used in combination with Hydroxychloroquine.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Carbinoxamine.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Hydroxychloroquine.]
[C07AG02, carvedilol, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Carvedilol.]
[N03AX24, cannabidiol, The therapeutic efficacy of Cannabidiol can be decreased when used in combination with Hydroxychloroquine.]
[B02BX08, avatrombopag, The metabolism of Hydroxychloroquine can be increased when combined with Avatrombopag.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Baricitinib.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Hydroxychloroquine.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Hydroxychloroquine.]
[L01XX62, ivosidenib, The metabolism of Hydroxychloroquine can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Hydroxychloroquine.]
[N03AX17, stiripentol, The therapeutic efficacy of Stiripentol can be decreased when used in combination with Hydroxychloroquine.]
[J05AX24, tecovirimat, The metabolism of Hydroxychloroquine can be increased when combined with Tecovirimat.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Hydroxychloroquine.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Hydroxychloroquine.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be increased when used in combination with Hydroxychloroquine.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Chloroprocaine.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Inotersen.]
[R03BB08, revefenacin, The metabolism of Revefenacin can be decreased when combined with Hydroxychloroquine.]
[L04AA39, emapalumab, The metabolism of Hydroxychloroquine can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Hydroxychloroquine.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Amifampridine.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Ravulizumab.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Cibenzoline.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Hydroxychloroquine.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Triclabendazole.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Siponimod.]
[J01FA09, clarithromycin, The metabolism of Hydroxychloroquine can be decreased when combined with Clarithromycin.]
[N06AX29, brexanolone, The therapeutic efficacy of Brexanolone can be decreased when used in combination with Hydroxychloroquine.]
[N05BA09, clobazam, The therapeutic efficacy of Clobazam can be decreased when used in combination with Hydroxychloroquine.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Cloprednol.]
[C09CA06, candesartan, The metabolism of Hydroxychloroquine can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Hydroxychloroquine can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Risankizumab.]
[L01EM03, alpelisib, The metabolism of Hydroxychloroquine can be decreased when combined with Alpelisib.]
[N05AA06, cyamemazine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Cyamemazine.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Cicletanine.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Upadacitinib.]
[L01EJ02, fedratinib, The metabolism of Hydroxychloroquine can be decreased when combined with Fedratinib.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Hydroxychloroquine can be decreased when it is combined with Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Hydroxychloroquine.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Hydroxychloroquine.]
[G04BE04, yohimbine, The metabolism of Yohimbine can be decreased when combined with Hydroxychloroquine.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be increased when used in combination with Hydroxychloroquine.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Hydroxychloroquine.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Trastuzumab emtansine.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Diroximel fumarate.]
[N03AX25, cenobamate, The therapeutic efficacy of Cenobamate can be decreased when used in combination with Hydroxychloroquine.]
[A16AX16, givosiran, The serum concentration of Hydroxychloroquine can be increased when it is combined with Givosiran.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Hydroxychloroquine.]
[R06AB02, dexchlorpheniramine, The metabolism of Dexchlorpheniramine can be decreased when combined with Hydroxychloroquine.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Teprotumumab.]
[M01AX21, diacetylrhein, The metabolism of Hydroxychloroquine can be decreased when combined with Diacerein.]
[J05AB16, remdesivir, The therapeutic efficacy of Remdesivir can be decreased when used in combination with Hydroxychloroquine.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Hydroxychloroquine.]
[H02CA02, osilodrostat, The metabolism of Hydroxychloroquine can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Hydroxychloroquine can be decreased when combined with Amprenavir.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Ozanimod.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Hydroxychloroquine.]
[N02AA08, dihydrocodeine, The metabolism of Dihydrocodeine can be decreased when combined with Hydroxychloroquine.]
[N02CC06, eletriptan, The metabolism of Eletriptan can be decreased when combined with Hydroxychloroquine.]
[M01AH02, rofecoxib, The metabolism of Hydroxychloroquine can be decreased when combined with Rofecoxib.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Hydroxychloroquine.]
[C08CA16, clevidipine, The metabolism of Clevidipine can be decreased when combined with Hydroxychloroquine.]
[C01BD07, dronedarone, The metabolism of Hydroxychloroquine can be decreased when combined with Dronedarone.]
[N03AG02, dipropylacetamide, The therapeutic efficacy of Valpromide can be decreased when used in combination with Hydroxychloroquine.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Hydroxychloroquine.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Hydroxychloroquine.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Chlorcyclizine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Hydroxychloroquine.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Fluprednidene.]
[G04BD09, trospium, The metabolism of Hydroxychloroquine can be decreased when combined with Trospium.]
[L01EX22, selpercatinib, The serum concentration of Hydroxychloroquine can be increased when it is combined with Selpercatinib.]
[N05CM02, chlormethiazole, The therapeutic efficacy of Clomethiazole can be decreased when used in combination with Hydroxychloroquine.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Hydroxychloroquine is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Stepronin is combined with Hydroxychloroquine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Fostemsavir.]
[P01BB01, proguanil, The metabolism of Hydroxychloroquine can be decreased when combined with Proguanil.]
[L04AC19, satralizumab, The serum concentration of Hydroxychloroquine can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The metabolism of Oliceridine can be decreased when combined with Hydroxychloroquine.]
[P01BA01, chloroquine, The metabolism of Hydroxychloroquine can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The metabolism of Hydroxychloroquine can be decreased when combined with Pralsetinib.]
[R06AB04, chlorpheniramine, The metabolism of Hydroxychloroquine can be decreased when combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Hydroxychloroquine can be decreased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Hydroxychloroquine.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Hydroxychloroquine.]
[M03BB03, chlorzoxazone, The metabolism of Chlorzoxazone can be decreased when combined with Hydroxychloroquine.]
[A11CC05, cholecalciferol, The metabolism of Hydroxychloroquine can be decreased when combined with Cholecalciferol.]
[N06BX18, vinpocetine, The therapeutic efficacy of Vinpocetine can be decreased when used in combination with Hydroxychloroquine.]
[B06AC06, berotralstat, The metabolism of Hydroxychloroquine can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Hydroxychloroquine can be decreased when combined with Lonafarnib.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Fludarabine is combined with Hydroxychloroquine.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Relugolix.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Hydroxychloroquine can be increased when it is combined with Abametapir.]
[N03AX10, felbamate, The therapeutic efficacy of Felbamate can be decreased when used in combination with Hydroxychloroquine.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Flumequine.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Hydroxychloroquine.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Hydroxychloroquine.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Hydroxychloroquine.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be increased when used in combination with Hydroxychloroquine.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Hydroxychloroquine.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Hydroxychloroquine.]
[A02BA01, cimetidine, The metabolism of Hydroxychloroquine can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Hydroxychloroquine.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Hydroxychloroquine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Hydroxychloroquine can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Hydroxychloroquine can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Hydroxychloroquine.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Citalopram.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Pegcetacoplan.]
[C03DA05, finerenone, The metabolism of Finerenone can be decreased when combined with Hydroxychloroquine.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Belumosudil.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Fexinidazole.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Anifrolumab.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Clemastine.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be increased when used in combination with Hydroxychloroquine.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be increased when used in combination with Hydroxychloroquine.]
[N06AX25, St. John's wort extract, The metabolism of Hydroxychloroquine can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Ropeginterferon alfa-2b.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Hydroxychloroquine.]
[B06AX04, mitapivat, The metabolism of Hydroxychloroquine can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Pacritinib.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Hydroxychloroquine.]
[N03AE01, clonazepam, The therapeutic efficacy of Clonazepam can be decreased when used in combination with Hydroxychloroquine.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Hydroxychloroquine.]
[C01EB24, mavacamten, The serum concentration of Hydroxychloroquine can be decreased when it is combined with Mavacamten.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be increased when used in combination with Hydroxychloroquine.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Deucravacitinib.]
[H01CC04, linzagolix, The serum concentration of Hydroxychloroquine can be increased when it is combined with Linzagolix.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Hydroxychloroquine.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Granisetron.]
[N05AH02, clozapine, The metabolism of Hydroxychloroquine can be decreased when combined with Clozapine.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be increased when used in combination with Hydroxychloroquine.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be increased when used in combination with Hydroxychloroquine.]
[H01AC08, somatrogon, The metabolism of Hydroxychloroquine can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Cocaine.]
[L04AC21, bimekizumab, The metabolism of Hydroxychloroquine can be increased when combined with Bimekizumab.]
[R05DA04, codeine, The metabolism of Codeine can be decreased when combined with Hydroxychloroquine.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Leflunomide.]
[A02AD04, hydrotalcite, Hydrotalcite can cause a decrease in the absorption of Hydroxychloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Hydroxychloroquine.]
[C04AX28, ifenprodil, The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Hydroxychloroquine.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be increased when used in combination with Hydroxychloroquine.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be increased when used in combination with Hydroxychloroquine.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Nelarabine is combined with Hydroxychloroquine.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be increased when used in combination with Hydroxychloroquine.]
[J01FA15, telithromycin, The metabolism of Hydroxychloroquine can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Ciclesonide is combined with Hydroxychloroquine.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Desloratadine.]
[C01AA06, lanatoside C, The serum concentration of Lanatoside C can be increased when it is combined with Hydroxychloroquine.]
[N02CC05, almotriptan, The metabolism of Hydroxychloroquine can be decreased when combined with Almotriptan.]
[J02AC02, itraconazole, The metabolism of Hydroxychloroquine can be decreased when combined with Itraconazole.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Emedastine.]
[L01EA01, imatinib, The serum concentration of Hydroxychloroquine can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Hydroxychloroquine can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Lacidipine.]
[N03AX09, lamotrigine, The therapeutic efficacy of Lamotrigine can be decreased when used in combination with Hydroxychloroquine.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Hydroxychloroquine.]
[N07BC04, lofexidine, The metabolism of Lofexidine can be decreased when combined with Hydroxychloroquine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Lomefloxacin.]
[R06AX13, loratadine, The metabolism of Hydroxychloroquine can be decreased when combined with Loratadine.]
[A02AD02, magaldrate, Magaldrate can cause a decrease in the absorption of Hydroxychloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A06AD01, magnesium carbonate, Magnesium carbonate can cause a decrease in the absorption of Hydroxychloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08CA11, manidipine, The metabolism of Hydroxychloroquine can be decreased when combined with Manidipine.]
[C07AA14, mepindolol, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Mepindolol.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Meprednisone.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Hydroxychloroquine.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Adenosine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Hydroxychloroquine.]
[N05AD03, metylperon, The metabolism of Hydroxychloroquine can be decreased when combined with Melperone.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Hydroxychloroquine.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be increased when used in combination with Hydroxychloroquine.]
[L01AA01, cyclophosphamide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Hydroxychloroquine.]
[N06AX07, minaprine, The metabolism of Minaprine can be decreased when combined with Hydroxychloroquine.]
[S01XA18, cyclosporine, Hydroxychloroquine may increase the immunosuppressive activities of Cyclosporine.]
[N06AG02, moclobemide, The metabolism of Hydroxychloroquine can be decreased when combined with Moclobemide.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Hydroxychloroquine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Hydroxychloroquine.]
[C03XA02, conivaptan, The metabolism of Hydroxychloroquine can be decreased when combined with Conivaptan.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Hydroxychloroquine.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Hydroxychloroquine.]
[M01AH05, etoricoxib, The metabolism of Hydroxychloroquine can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Hydroxychloroquine.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Hydroxychloroquine.]
[G03XA01, danazol, The metabolism of Hydroxychloroquine can be decreased when combined with Danazol.]
[J04BA02, dapsone, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Dapsone.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Hydroxychloroquine.]
[C02CC04, debrisoquin, The metabolism of Debrisoquine can be decreased when combined with Hydroxychloroquine.]
[C07AB12, nebivolol, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Nebivolol.]
[N06AX06, nefazodone, The metabolism of Hydroxychloroquine can be decreased when combined with Nefazodone.]
[L02BB02, nilutamide, The metabolism of Hydroxychloroquine can be decreased when combined with Nilutamide.]
[N03AG06, tiagabine, The therapeutic efficacy of Tiagabine can be decreased when used in combination with Hydroxychloroquine.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Hydroxychloroquine.]
[N06AB10, escitalopram, The serum concentration of Hydroxychloroquine can be increased when it is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Hydroxychloroquine.]
[N06AA01, desipramine, The metabolism of Hydroxychloroquine can be decreased when combined with Desipramine.]
[C01AA07, deslanoside, The serum concentration of Deslanoside can be increased when it is combined with Hydroxychloroquine.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Hydroxychloroquine.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Hydroxychloroquine.]
[N03AF02, oxcarbazepine, The therapeutic efficacy of Oxcarbazepine can be decreased when used in combination with Hydroxychloroquine.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Dexamethasone is combined with Hydroxychloroquine.]
[G04BD04, oxybutynin, The metabolism of Hydroxychloroquine can be decreased when combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Hydroxychloroquine.]
[L04AB04, adalimumab, The metabolism of Hydroxychloroquine can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Gefitinib can be decreased when combined with Hydroxychloroquine.]
[N06BA02, dextroamphetamine, The metabolism of Amphetamine can be decreased when combined with Hydroxychloroquine.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be decreased when combined with Hydroxychloroquine.]
[N03AC01, paramethadione, The therapeutic efficacy of Paramethadione can be decreased when used in combination with Hydroxychloroquine.]
[N06AB05, paroxetine, The metabolism of Hydroxychloroquine can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Hydroxychloroquine can be decreased when combined with Clopidogrel.]
[N05BA01, diazepam, The therapeutic efficacy of Diazepam can be decreased when used in combination with Hydroxychloroquine.]
[N03AX07, phenacemide, The therapeutic efficacy of Phenacemide can be decreased when used in combination with Hydroxychloroquine.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Phenol.]
[N03AD02, phensuximide, The therapeutic efficacy of Phensuximide can be decreased when used in combination with Hydroxychloroquine.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Cinchocaine.]
[S01BC03, diclofenac, The metabolism of Hydroxychloroquine can be decreased when combined with Diclofenac.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Hydroxychloroquine.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Pinaverium.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Hydroxychloroquine.]
[L01DC04, ixabepilone, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Ixabepilone.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Hydroxychloroquine.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Pirarubicin.]
[L02AA01, diethylstilbestrol, The metabolism of Hydroxychloroquine can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Hydroxychloroquine can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Difluocortolone.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Hydroxychloroquine.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Hydroxychloroquine.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Hydroxychloroquine.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Hydroxychloroquine.]
[J05AE08, atazanavir, The metabolism of Hydroxychloroquine can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Hydroxychloroquine.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Hydroxychloroquine can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Dimenhydrinate.]
[M02AX03, dimethyl sulfoxide, The metabolism of Hydroxychloroquine can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The therapeutic efficacy of Progabide can be decreased when used in combination with Hydroxychloroquine.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Diphenhydramine.]
[A03FA02, cisapride, The metabolism of Hydroxychloroquine can be decreased when combined with Cisapride.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Sirolimus is combined with Hydroxychloroquine.]
[N05AL04, remoxipride, The metabolism of Remoxipride can be decreased when combined with Hydroxychloroquine.]
[C01BA03, disopyramide, The therapeutic efficacy of Disopyramide can be increased when used in combination with Hydroxychloroquine.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Natalizumab.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Hydroxychloroquine.]
[S02AA12, rifamycin SV, The metabolism of Hydroxychloroquine can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Hydroxychloroquine can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The therapeutic efficacy of Riluzole can be decreased when used in combination with Hydroxychloroquine.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Risperidone is combined with Hydroxychloroquine.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Levocetirizine.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Hydroxychloroquine.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Hydroxychloroquine.]
[L01EX01, sunitinib, The therapeutic efficacy of Sunitinib can be increased when used in combination with Hydroxychloroquine.]
[A04AD12, aprepitant, The metabolism of Hydroxychloroquine can be decreased when combined with Aprepitant.]
[L01XG01, bortezomib, The risk or severity of adverse effects can be increased when Bortezomib is combined with Hydroxychloroquine.]
[S01BC05, ketorolac, The metabolism of Hydroxychloroquine can be decreased when combined with Ketorolac.]
[C01EB18, ranolazine, The serum concentration of Hydroxychloroquine can be increased when it is combined with Ranolazine.]
[R03AC12, salmeterol, The metabolism of Hydroxychloroquine can be decreased when combined with Salmeterol.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Domperidone.]
[N06AA16, dothiepin, The metabolism of Hydroxychloroquine can be decreased when combined with Dosulepin.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Hydroxychloroquine.]
[L01DB01, doxorubicin, The risk or severity of adverse effects can be increased when Doxorubicin is combined with Hydroxychloroquine.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Hydroxychloroquine.]
[N06AB06, sertraline, The metabolism of Sertraline can be decreased when combined with Hydroxychloroquine.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Hydroxychloroquine.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Droperidol.]
[C10AA01, simvastatin, The metabolism of Hydroxychloroquine can be decreased when combined with Simvastatin.]
[B05XA02, sodium bicarbonate, Sodium bicarbonate can cause a decrease in the absorption of Hydroxychloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Sultopride.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Talinolol.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Corticotropin is combined with Hydroxychloroquine.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Temafloxacin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Hydroxychloroquine.]
[D01BA02, terbinafine, The metabolism of Hydroxychloroquine can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Terodiline.]
[C07AA16, tertatolol, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Tertatolol.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be decreased when combined with Hydroxychloroquine.]
[N03AX11, topiramate, The therapeutic efficacy of Topiramate can be decreased when used in combination with Hydroxychloroquine.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Toremifene.]
[C03CA04, torsemide, The metabolism of Hydroxychloroquine can be decreased when combined with Torasemide.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Trilostane is combined with Hydroxychloroquine.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Triptorelin.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Trofosfamide.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Hydroxychloroquine.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Vinorelbine is combined with Hydroxychloroquine.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Hydroxychloroquine.]
[N06AX16, venlafaxine, The metabolism of Hydroxychloroquine can be decreased when combined with Venlafaxine.]
[C08CA12, mepirodipine, The metabolism of Hydroxychloroquine can be decreased when combined with Barnidipine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Hydroxychloroquine.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be decreased when combined with Hydroxychloroquine.]
[N03AX15, zonisamide, The therapeutic efficacy of Zonisamide can be decreased when used in combination with Hydroxychloroquine.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be increased when used in combination with Hydroxychloroquine.]
[N05CF01, zopiclone, The metabolism of Hydroxychloroquine can be decreased when combined with Zopiclone.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Hydroxychloroquine.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Moricizine.]
[N02CA02, ergotamine, The metabolism of Hydroxychloroquine can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Hydroxychloroquine.]
[S01AA17, erythromycin, The metabolism of Hydroxychloroquine can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, The therapeutic efficacy of Estazolam can be decreased when used in combination with Hydroxychloroquine.]
[H05BX01, cinacalcet, The metabolism of Hydroxychloroquine can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Hydroxychloroquine can be decreased when combined with Estradiol.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Estramustine is combined with Hydroxychloroquine.]
[J04AK02, ethambutol, The metabolism of Hydroxychloroquine can be decreased when combined with Ethambutol.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Hydroxychloroquine can be decreased when combined with Fluvastatin.]
[L02AA03, ethinyl estradiol, The metabolism of Hydroxychloroquine can be decreased when combined with Ethinylestradiol.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Ibutilide.]
[N03AD01, ethosuximide, The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Hydroxychloroquine.]
[N03AB01, ethotoin, The therapeutic efficacy of Ethotoin can be decreased when used in combination with Hydroxychloroquine.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Meloxicam.]
[S01XA06, ethylmorphine, The metabolism of Ethylmorphine can be decreased when combined with Hydroxychloroquine.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Etidocaine.]
[L01CB01, etoposide, The risk or severity of adverse effects can be increased when Etoposide is combined with Hydroxychloroquine.]
[N05AE03, sertindole, The metabolism of Sertindole can be decreased when combined with Hydroxychloroquine.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Hydroxychloroquine.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Hydroxychloroquine.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Fleroxacin.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Hydroxychloroquine.]
[R06AX12, terfenadine, The metabolism of Hydroxychloroquine can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The metabolism of Hydroxychloroquine can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Hydroxychloroquine can be decreased when combined with Fluvoxamine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Hydroxychloroquine.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Leuprolide.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Hydroxychloroquine.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Hydroxychloroquine.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Hydroxychloroquine.]
[C08CA02, felodipine, The metabolism of Hydroxychloroquine can be decreased when combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Fendiline.]
[N03AX26, fenfluramine, The therapeutic efficacy of Fenfluramine can be decreased when used in combination with Hydroxychloroquine.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Hydroxychloroquine.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Hydroxychloroquine.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Hydroxychloroquine.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Hydroxychloroquine.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Hydroxychloroquine.]
[J02AC01, fluconazole, The metabolism of Hydroxychloroquine can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Flucytosine is combined with Hydroxychloroquine.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Hydroxychloroquine.]
[N07CA03, flunarizine, The therapeutic efficacy of Flunarizine can be decreased when used in combination with Hydroxychloroquine.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Fluocinonide is combined with Hydroxychloroquine.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Fluocortolone.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Hydroxychloroquine.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Hydroxychloroquine.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Hydroxychloroquine.]
[N06AB03, fluoxetine, The serum concentration of Hydroxychloroquine can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Fluphenazine.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Fluspirilene.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Hydroxychloroquine.]
[J05AE10, darunavir, The metabolism of Hydroxychloroquine can be decreased when combined with Darunavir.]
[N05CF04, eszopiclone, The metabolism of Hydroxychloroquine can be decreased when combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Hydroxychloroquine.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Gallopamil.]
[N03AA04, barbexaclone, The therapeutic efficacy of Barbexaclone can be decreased when used in combination with Hydroxychloroquine.]
[C10AB04, gemfibrozil, The metabolism of Hydroxychloroquine can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Degarelix.]
[L01EA02, dasatinib, The risk or severity of adverse effects can be increased when Dasatinib is combined with Hydroxychloroquine.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be increased when used in combination with Hydroxychloroquine.]
[N03AD03, methsuximide, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Hydroxychloroquine.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Hydroxychloroquine.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be increased when used in combination with Hydroxychloroquine.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be increased when used in combination with Hydroxychloroquine.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be increased when used in combination with Hydroxychloroquine.]
[N05CM18, dexmedetomidine, The metabolism of Hydroxychloroquine can be decreased when combined with Dexmedetomidine.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Dofetilide.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Hydroxychloroquine.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Hydroxychloroquine.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Esmolol.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Goserelin.]
[P01BX01, halofantrine, The metabolism of Hydroxychloroquine can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Histrelin.]
[N05AH04, quetiapine, The metabolism of Quetiapine can be decreased when combined with Hydroxychloroquine.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be increased when used in combination with Hydroxychloroquine.]
[L01CE02, irinotecan, The risk or severity of adverse effects can be increased when Irinotecan is combined with Hydroxychloroquine.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Hydroxychloroquine.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Hydroxychloroquine.]
[N05CA16, hexobarbital, The therapeutic efficacy of Hexobarbital can be decreased when used in combination with Hydroxychloroquine.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Hydroxychloroquine.]
[C08CA10, nilvadipine, The metabolism of Hydroxychloroquine can be decreased when combined with Nilvadipine.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Oxatomide.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Hydroxychloroquine.]
[R05DA03, hydrocodone, The metabolism of Hydrocodone can be decreased when combined with Hydroxychloroquine.]
[S02BA01, hydrocortisone, The metabolism of Hydroxychloroquine can be increased when combined with Hydrocortisone.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Hydrocortisone butyrate.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Antilymphocyte immunoglobulin (horse).]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Pipemidic acid.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Fluticasone furoate.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Hydroxychloroquine.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Hydroxychloroquine can be increased when combined with Rifabutin.]
[R02AX02, ibuprofen, The metabolism of Hydroxychloroquine can be decreased when combined with Ibuprofen.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Idarubicin is combined with Hydroxychloroquine.]
[L01AA06, ifosfamide, The risk or severity of adverse effects can be increased when Ifosfamide is combined with Hydroxychloroquine.]
[N06AA02, imipramine, The metabolism of Hydroxychloroquine can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Hydroxychloroquine.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Terlipressin.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Tixocortol.]
[M03BX02, tizanidine, The therapeutic efficacy of Tizanidine can be decreased when used in combination with Hydroxychloroquine.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Topotecan is combined with Hydroxychloroquine.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Hydroxychloroquine.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Hydroxychloroquine.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Hydroxychloroquine.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Hydroxychloroquine.]
[N06AX17, milnacipran, The metabolism of Hydroxychloroquine can be decreased when combined with Milnacipran.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Eculizumab is combined with Hydroxychloroquine.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Articaine.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be increased when used in combination with Hydroxychloroquine.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Hydroxychloroquine.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be increased when used in combination with Hydroxychloroquine.]
[C10AA06, cerivastatin, The metabolism of Hydroxychloroquine can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Anagrelide.]
[C07AA01, alprenolol, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Alprenolol.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Hydroxychloroquine.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Hydroxychloroquine.]
[N06AF05, iproniazid, The metabolism of Hydroxychloroquine can be decreased when combined with Iproniazid.]
[N05AA07, chlorproethazine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Chlorproethazine.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Hydroxychloroquine.]
[N04BX02, entacapone, The metabolism of Hydroxychloroquine can be decreased when combined with Entacapone.]
[J04AC01, isoniazid, The metabolism of Hydroxychloroquine can be decreased when combined with Isoniazid.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be increased when used in combination with Hydroxychloroquine.]
[N06AX18, reboxetine, The metabolism of Hydroxychloroquine can be decreased when combined with Reboxetine.]
[A07BC02, kaolin, Kaolin can cause a decrease in the absorption of Hydroxychloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AB01, aluminum hydroxide, Aluminum hydroxide can cause a decrease in the absorption of Hydroxychloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AC07, tocilizumab, The metabolism of Hydroxychloroquine can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Hydroxychloroquine can be decreased when combined with Ketamine.]
[J02AB02, ketoconazole, The metabolism of Hydroxychloroquine can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Hydroxychloroquine.]
[M02AA10, ketoprofen, The metabolism of Hydroxychloroquine can be decreased when combined with Ketoprofen.]
[V03AC03, deferasirox, The metabolism of Hydroxychloroquine can be decreased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Hydroxychloroquine can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Mizolastine.]
[N04BC09, rotigotine, The metabolism of Rotigotine can be decreased when combined with Hydroxychloroquine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Nalidixic acid.]
[C07AG01, labetalol, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Labetalol.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Hydroxychloroquine.]
[N03AX18, lacosamide, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Hydroxychloroquine.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Hydroxychloroquine.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Lidoflazine.]
[N02CA07, lisuride, The metabolism of Lisuride can be decreased when combined with Hydroxychloroquine.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Lomustine is combined with Hydroxychloroquine.]
[A07DA03, loperamide, The metabolism of Hydroxychloroquine can be decreased when combined with Loperamide.]
[N05BA06, lorazepam, The therapeutic efficacy of Lorazepam can be decreased when used in combination with Hydroxychloroquine.]
[C10AA02, lovastatin, The metabolism of Hydroxychloroquine can be decreased when combined with Lovastatin.]
[L01EG01, temsirolimus, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Temsirolimus.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide can cause a decrease in the absorption of Hydroxychloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC10, magnesium oxide, Magnesium oxide can cause a decrease in the absorption of Hydroxychloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Hydroxychloroquine.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Pralatrexate.]
[L01EA03, nilotinib, The metabolism of Hydroxychloroquine can be decreased when combined with Nilotinib.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Hydroxychloroquine.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Hydroxychloroquine.]
[R06AE05, meclizine, The metabolism of Meclizine can be decreased when combined with Hydroxychloroquine.]
[N05BA03, medazepam, The therapeutic efficacy of Medazepam can be decreased when used in combination with Hydroxychloroquine.]
[C01AA08, medigoxin, The serum concentration of Metildigoxin can be increased when it is combined with Hydroxychloroquine.]
[P01BC02, mefloquine, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Mefloquine.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Melphalan is combined with Hydroxychloroquine.]
[N03AB04, mephenytoin, The therapeutic efficacy of Mephenytoin can be decreased when used in combination with Hydroxychloroquine.]
[N03AA01, mephobarbital, The therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Hydroxychloroquine.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Mepivacaine.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Paliperidone.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be increased when used in combination with Hydroxychloroquine.]
[A04AA04, dolasetron, The metabolism of Dolasetron can be decreased when combined with Hydroxychloroquine.]
[N07BC02, methadone, The metabolism of Hydroxychloroquine can be decreased when combined with Methadone.]
[N06BA03, methamphetamine, The metabolism of Metamfetamine can be decreased when combined with Hydroxychloroquine.]
[N03AA30, metharbital, The therapeutic efficacy of Metharbital can be decreased when used in combination with Hydroxychloroquine.]
[H03BB02, methimazole, The metabolism of Hydroxychloroquine can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Hydroxychloroquine.]
[N05CA15, methohexital, The therapeutic efficacy of Methohexital can be decreased when used in combination with Hydroxychloroquine.]
[L04AX03, methotrexate, The serum concentration of Methotrexate can be decreased when it is combined with Hydroxychloroquine.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Methotrimeprazine.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be decreased when combined with Hydroxychloroquine.]
[V04CG05, methylene blue, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Methylene blue.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Hydroxychloroquine.]
[N03AF03, rufinamide, The therapeutic efficacy of Rufinamide can be decreased when used in combination with Hydroxychloroquine.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Hydroxychloroquine.]
[C07AB02, metoprolol, The metabolism of Hydroxychloroquine can be decreased when combined with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Hydroxychloroquine.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Hydroxychloroquine.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Hydroxychloroquine.]
[S02AA13, miconazole, The metabolism of Hydroxychloroquine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Hydroxychloroquine can be decreased when combined with Aminophenazone.]
[G03XB01, mifepristone, The serum concentration of Hydroxychloroquine can be increased when it is combined with Mifepristone.]
[L01XX23, mitotane, The metabolism of Hydroxychloroquine can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Hydroxychloroquine.]
[N06BA12, lisdexamfetamine, The metabolism of Lisdexamfetamine can be decreased when combined with Hydroxychloroquine.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydroxychloroquine.]
[C01BD01, amiodarone, The metabolism of Hydroxychloroquine can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Hydroxychloroquine.]
[N02AA01, morphine, The metabolism of Hydroxychloroquine can be decreased when combined with Morphine.]
[A04AA05, palonosetron, The metabolism of Palonosetron can be decreased when combined with Hydroxychloroquine.]
[L04AB05, certolizumab pegol, The metabolism of Hydroxychloroquine can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Hydroxychloroquine can be decreased when combined with Eltrombopag.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Ofatumumab.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Hydroxychloroquine.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Hydroxychloroquine.]
[N05CA02, amobarbital, The therapeutic efficacy of Amobarbital can be decreased when used in combination with Hydroxychloroquine.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Hydroxychloroquine.]
[G03XC01, raloxifene, The metabolism of Hydroxychloroquine can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Hydroxychloroquine.]
[N03AB05, fosphenytoin, The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Hydroxychloroquine.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Hydroxychloroquine.]
[C07AA12, nadolol, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Nadolol.]
[V03AB15, naloxone, The metabolism of Hydroxychloroquine can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Hydroxychloroquine can be increased when combined with Anakinra.]
[N06BA01, amphetamine, The metabolism of Amphetamine can be decreased when combined with Hydroxychloroquine.]
[M02AA12, naproxen, The metabolism of Hydroxychloroquine can be decreased when combined with Naproxen.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be increased when used in combination with Hydroxychloroquine.]
[N06AX21, duloxetine, The metabolism of Hydroxychloroquine can be decreased when combined with Duloxetine.]
[L01CD02, docetaxel, The risk or severity of adverse effects can be increased when Docetaxel is combined with Hydroxychloroquine.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be increased when used in combination with Hydroxychloroquine.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Levosimendan.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Iloperidone.]
[S01AA19, ampicillin, Hydroxychloroquine can cause a decrease in the absorption of Ampicillin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AX23, desvenlafaxine, The metabolism of Hydroxychloroquine can be decreased when combined with Desvenlafaxine.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Hydroxychloroquine.]
[C10AD02, niacin, The metabolism of Hydroxychloroquine can be decreased when combined with Niacin.]
[C08CA04, nicardipine, The metabolism of Hydroxychloroquine can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, The metabolism of Nicergoline can be decreased when combined with Hydroxychloroquine.]
[C08CA05, nifedipine, The metabolism of Nifedipine can be decreased when combined with Hydroxychloroquine.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Nimodipine.]
[N05CD02, nitrazepam, The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Hydroxychloroquine.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Hydroxychloroquine.]
[N05CF03, zaleplon, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Hydroxychloroquine.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Hydroxychloroquine.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Hydroxychloroquine.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hydroxychloroquine.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Ofloxacin.]
[L04AC04, rilonacept, The metabolism of Hydroxychloroquine can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Hydroxychloroquine can be decreased when combined with Omeprazole.]
[N02AA02, opium, The metabolism of Opium can be decreased when combined with Hydroxychloroquine.]
[G04CA02, tamsulosin, The metabolism of Tamsulosin can be decreased when combined with Hydroxychloroquine.]
[C01AC01, ouabain, The serum concentration of Ouabain can be increased when it is combined with Hydroxychloroquine.]
[P02BA02, oxamniquine, The metabolism of Hydroxychloroquine can be decreased when combined with Oxamniquine.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Oxolinic acid.]
[C07AA02, oxprenolol, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Oxprenolol.]
[N02AA05, oxycodone, The metabolism of Oxycodone can be decreased when combined with Hydroxychloroquine.]
[N02AA11, oxymorphone, The metabolism of Oxymorphone can be decreased when combined with Hydroxychloroquine.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Hydroxychloroquine.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Asenapine.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Papaverine.]
[N05CC05, paraldehyde, The therapeutic efficacy of Paraldehyde can be decreased when used in combination with Hydroxychloroquine.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Paramethasone is combined with Hydroxychloroquine.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Hydroxychloroquine.]
[G04BD11, fesoterodine, The metabolism of Fesoterodine can be decreased when combined with Hydroxychloroquine.]
[C07AA23, penbutolol, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Penfluridol.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Hydroxychloroquine.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Hydroxychloroquine.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Hydroxychloroquine.]
[N05CA01, pentobarbital, The therapeutic efficacy of Pentobarbital can be decreased when used in combination with Hydroxychloroquine.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Hydroxychloroquine.]
[N05AB10, perazine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Perazine.]
[C08EX02, perhexiline, The metabolism of Hydroxychloroquine can be decreased when combined with Perhexiline.]
[N05AB03, perphenazine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Perphenazine.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Hydroxychloroquine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Hydroxychloroquine.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be increased when used in combination with Hydroxychloroquine.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Pheniramine.]
[N03AA02, phenobarbital, The therapeutic efficacy of Phenobarbital can be decreased when used in combination with Hydroxychloroquine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Hydroxychloroquine.]
[N03AB02, phenytoin, The therapeutic efficacy of Phenytoin can be decreased when used in combination with Hydroxychloroquine.]
[L04AB06, golimumab, The metabolism of Hydroxychloroquine can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Levofloxacin.]
[C08CX01, mibefradil, The metabolism of Hydroxychloroquine can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Hydroxychloroquine.]
[C07AA03, pindolol, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Hydroxychloroquine can be decreased when combined with Atorvastatin.]
[J05AE01, saquinavir, The metabolism of Hydroxychloroquine can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Hydroxychloroquine.]
[N05AC04, pipothiazine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Pipotiazine.]
[S01BC06, piroxicam, The metabolism of Hydroxychloroquine can be decreased when combined with Piroxicam.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Grepafloxacin.]
[J05AG02, delavirdine, The metabolism of Hydroxychloroquine can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Hydroxychloroquine can be decreased when combined with Irbesartan.]
[D05AX05, tazarotene, The metabolism of Hydroxychloroquine can be decreased when combined with Tazarotene.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be increased when used in combination with Hydroxychloroquine.]
[L02BG03, anastrozole, The metabolism of Hydroxychloroquine can be decreased when combined with Anastrozole.]
[L04AC08, canakinumab, The metabolism of Hydroxychloroquine can be increased when combined with Canakinumab.]
[J05AE03, ritonavir, The serum concentration of Hydroxychloroquine can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be increased when used in combination with Hydroxychloroquine.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be increased when used in combination with Hydroxychloroquine.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Hydroxychloroquine.]
[C07AB01, practolol, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Practolol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Prajmaline.]
[P02BA01, praziquantel, Hydroxychloroquine can cause a decrease in the absorption of Praziquantel resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Prednisolone is combined with Hydroxychloroquine.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Hydroxychloroquine.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Hydroxychloroquine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The therapeutic efficacy of Primidone can be decreased when used in combination with Hydroxychloroquine.]
[M04AB01, probenecid, The metabolism of Hydroxychloroquine can be increased when combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Probucol.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Hydroxychloroquine.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Hydroxychloroquine.]
[C10AB05, fenofibrate, The metabolism of Hydroxychloroquine can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Prochlorperazine.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Hydroxychloroquine.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Promazine.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Promethazine.]
[C01BC03, propafenone, The metabolism of Hydroxychloroquine can be decreased when combined with Propafenone.]
[N05AC01, periciazine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Periciazine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Hydroxychloroquine.]
[N02AC04, propoxyphene, The metabolism of Hydroxychloroquine can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Propranolol.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Hydroxychloroquine.]
[C01AB01, proscillaridin, The serum concentration of Proscillaridin can be increased when it is combined with Hydroxychloroquine.]
[R03DC03, montelukast, The metabolism of Hydroxychloroquine can be decreased when combined with Montelukast.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Hydroxychloroquine.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Hydroxychloroquine.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Hydroxychloroquine.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Mepyramine.]
[P01BD01, pyrimethamine, The metabolism of Hydroxychloroquine can be decreased when combined with Pyrimethamine.]
[C01BA01, quinidine, The metabolism of Hydroxychloroquine can be decreased when combined with Quinidine.]
[P01BC01, quinine, The therapeutic efficacy of Quinine can be increased when used in combination with Hydroxychloroquine.]
[A02BA02, ranitidine, The metabolism of Hydroxychloroquine can be decreased when combined with Ranitidine.]
[J04AB02, rifampin, The metabolism of Hydroxychloroquine can be increased when combined with Rifampicin.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Roxithromycin.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Hydroxychloroquine.]
[N05CA06, secobarbital, The therapeutic efficacy of Secobarbital can be decreased when used in combination with Hydroxychloroquine.]
[N04BD01, selegiline, The metabolism of Hydroxychloroquine can be decreased when combined with Selegiline.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Hydroxychloroquine.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Hydroxychloroquine.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Hydroxychloroquine.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Hydroxychloroquine.]
[C03DA01, spironolactone, The metabolism of Hydroxychloroquine can be decreased when combined with Spironolactone.]
[H02CA04, levoketoconazole, The metabolism of Hydroxychloroquine can be decreased when combined with Levoketoconazole.]
[N05AL01, sulpiride, QT prolonging agents - QT prolonging agents]
[N05AC02, thioridazine, QT prolonging agents - QT prolonging agents]
[L01EX04, vandetanib, QT prolonging agents - QT prolonging agents]
[N06DA02, donepezil, QT prolonging agents - QT prolonging agents]
[S01AE07, moxifloxacin, QT prolonging agents - QT prolonging agents]
[C08EA02, bepridil, QT prolonging agents - QT prolonging agents]
[L01XX27, arsenic trioxide, QT prolonging agents - QT prolonging agents]
[J01MA09, sparfloxacin, QT prolonging agents - QT prolonging agents]
[S01AA26, azithromycin, QT prolonging agents - QT prolonging agents]
[B01AC23, cilostazol, QT prolonging agents - QT prolonging agents]
[J01FA09, clarithromycin, QT prolonging agents - QT prolonging agents]
[S01AE06, gatifloxacin, QT prolonging agents - QT prolonging agents]
[C01BD07, dronedarone, QT prolonging agents - QT prolonging agents]
[L01DB04, aclarubicin, QT prolonging agents - QT prolonging agents]
[P01BA01, chloroquine, QT prolonging agents - QT prolonging agents]
[N05AA01, chlorpromazine, QT prolonging agents - QT prolonging agents]
[N05AF03, chlorprothixene, QT prolonging agents - QT prolonging agents]
[S03AA07, ciprofloxacin, QT prolonging agents - QT prolonging agents]
[N06AB04, citalopram, QT prolonging agents - QT prolonging agents]
[L01EB10, mobocertinib, QT prolonging agents - QT prolonging agents]
[A04AA01, ondansetron, QT prolonging agents - QT prolonging agents]
[S02DA02, cocaine, QT prolonging agents - QT prolonging agents]
[C01BA13, hydroquinidine, QT prolonging agents - QT prolonging agents]
[P01CB01, meglumine antimoniate, QT prolonging agents - QT prolonging agents]
[L01XA03, oxaliplatin, QT prolonging agents - QT prolonging agents]
[A03FA02, cisapride, QT prolonging agents - QT prolonging agents]
[C01BA03, disopyramide, QT prolonging agents - QT prolonging agents]
[A03FA03, domperidone, QT prolonging agents - QT prolonging agents]
[N01AB08, sevoflurane, QT prolonging agents - QT prolonging agents]
[N05AD08, droperidol, QT prolonging agents - QT prolonging agents]
[N05AL02, sultopride, QT prolonging agents - QT prolonging agents]
[G04BD05, terodiline, QT prolonging agents - QT prolonging agents]
[S01AA17, erythromycin, QT prolonging agents - QT prolonging agents]
[C01BD05, ibutilide, QT prolonging agents - QT prolonging agents]
[N05AE03, sertindole, QT prolonging agents - QT prolonging agents]
[R06AX11, astemizole, QT prolonging agents - QT prolonging agents]
[R06AX12, terfenadine, QT prolonging agents - QT prolonging agents]
[C01BC04, flecainide, QT prolonging agents - QT prolonging agents]
[J02AC01, fluconazole, QT prolonging agents - QT prolonging agents]
[C01BD04, dofetilide, QT prolonging agents - QT prolonging agents]
[P01BX01, halofantrine, QT prolonging agents - QT prolonging agents]
[N05AD01, haloperidol, QT prolonging agents - QT prolonging agents]
[H01BA04, terlipressin, QT prolonging agents - QT prolonging agents]
[L01XX35, anagrelide, QT prolonging agents - QT prolonging agents]
[N05AC03, mesoridazine, QT prolonging agents - QT prolonging agents]
[N07BC02, methadone, QT prolonging agents - QT prolonging agents]
[N05AA02, methotrimeprazine, QT prolonging agents - QT prolonging agents]
[C01BD01, amiodarone, QT prolonging agents - QT prolonging agents]
[S01AE05, levofloxacin, QT prolonging agents - QT prolonging agents]
[N05AG02, pimozide, QT prolonging agents - QT prolonging agents]
[J01MA11, grepafloxacin, QT prolonging agents - QT prolonging agents]
[C10AX02, probucol, QT prolonging agents - QT prolonging agents]
[C01BA02, procainamide, QT prolonging agents - QT prolonging agents]
[N01AX10, propofol, QT prolonging agents - QT prolonging agents]
[C01BA01, quinidine, QT prolonging agents - QT prolonging agents]
[J01FA06, roxithromycin, QT prolonging agents - QT prolonging agents]
[C07AA07, sotalol, QT prolonging agents - QT prolonging agents]
